DRG Perspective: A Snapshot into Current Trends and Development of New Therapeutics for Women’s Health (Part 1) – A Profile of Uterine Fibroids and Endometriosis
Historically, the women’s health pharmaceutical market has been an attractive segment and an area of commercial opportunity for drug developers,... In DRG Blog/ April, 2017 Will RNA Inhibiting Therapies Bring Meaningful Clinical Benefits in the Treatment of ATTR Amyloidosis?
What is amyloidosis and ATTR amyloidosis? Amyloidosis is a rare clinical disorder caused by the accumulation of aggregated, misfolded proteins in... In DRG Blog, Niche and Rare Disease/ April, 2017 Rare Diseases & Orphan Products Breakthrough Summit: Focus on Innovative Gene Technologies and Improved Access to Care
The 2016 Rare Diseases & Orphan Products Breakthrough Summit, a two-day conference led by the National Organization for Rare Disorders (NORD), was... In DRG Blog, Niche and Rare Disease/ November, 2016 While Kalydeco sailed through, Vertex’s Orkambi faces strong headwinds in Europe
Orkambi is the first therapy addressing the underlying cause of the disease in cystic fibrosis (CF) patients with two copies of the F508del mutation.... In DRG Blog, Niche and Rare Disease/ June, 2016